Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats
Animal research · 2015
- What was studied
- 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
- Main finding
- Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.
Reported findings and study design
Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.
Population or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Dose, route and schedule
Interventions were intraperitoneal once daily for four days before and three after cisplatin. Kidney complex 300 µg/kg, EDL 3 µg/kg, AED 3 µg/kg, AEDG 7 µg/kg. Cisplatin was a 6 mg/kg intraperitoneal injection 72 hours before sampling.
Protocol source ↗ · Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glomerular filtration rate | 433.3 kidney complex, 543.9 EDL, 305.1 AED, 469.9 AEDG vs 240.8 µL/min with cisplatin alone | |
| Plasma creatinine | 67.43 with kidney complex vs 94.91 µmol/L with cisplatin alone | p≤0.05 |
| Diuresis over two hours | 2.62 kidney complex, 3.02 EDL, 1.81 AED, 2.89 AEDG vs 1.50 mL with cisplatin alone |
Selected Table 1 values
| Outcome | Intact | Cisplatin | Kidney complex | EDL | AED | AEDG |
|---|---|---|---|---|---|---|
| Filtration, µL/min | 502.90 | 240.8 | 433.3 | 543.9 | 305.1 | 469.9 |
| Creatinine, µmol/L | 64.90 | 94.91 | 67.43 | 68.95 | 82.60 | 77.54 |
| Urine over two hours, mL | 4.12 | 1.50 | 2.62 | 3.02 | 1.81 | 2.89 |
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured.
- Each outcome applies to the specific arm and preparation tested.
Source details
Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
I. I. Zamorskii, T. S. Shchudrova, N. S. Lin’kova, T. E. Nichik, V. Kh. Khavinson. Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176.
Related compounds
Pielotax
A peptide mixture from calf or pig kidneys, studied in a Russian report on kidney laboratory measures.
EDL
Glu–Asp–Leu (EDL), a defined tripeptide studied in models of kidney-cell aging. Ovagen reports list the same constituent amino acids but do not establish the sequence of the tested product.
Cartalax
A synthetic tripeptide, Ala–Glu–Asp (AED, also called T-31), studied in cartilage, bone and joint research. Some related experiments used a cartilage extract containing AED.
Epitalon
A synthetic tetrapeptide, Ala–Glu–Asp–Gly (AEDG, also called Epithalon), developed from pineal-gland research. Human studies examined melatonin secretion, circadian markers and retinal function.